We have developed a novel cotransplantation system in which gene-transduced human CD34+ progenitor cells are transplanted into immunodeficient (bnx) mice together with primary human bone marrow (BM) stromal cells engineered to produce human interleukin-3 (IL-3). The IL-3-secreting stroma produced sustained circulating levels of human 11-3 for at least 4 months in the mice. The IL-3-secreting stroma, but not control stroma, supported human hematopoiesis from the cotransplanted human BM CD34' progenitors for up to 9 months, such that an average of 6% of the hematopoietic cells removed from the mice were of human origin (human CD&+). Human multilineage progenitors were readily detected as colony-forming units from the mouse marrow over this time period. Retroviral-mediated transfer UCCESSFUL GENE therapy of genetic diseases involving hematopoietic cells requires long-term expression of an exogenous gene after transfer into human bone marrow (BM) stem cells. Retroviral vector-mediated transduction of murine hematopoietic stem cells has been convincingly shown.'.' However, there has been no comparable demonstration of human hematopoietic stem cell transduction, because of the lack of an experimental in vivo transplantation system. Several groups have used xenogeneic BM transplantation (BMT) into immunodeficient mice to study human hematopoiesis, and such a system may be used to study gene transduction of human stem cells. Two of the models that have been developed require surgical implantation of human fetal liver and thy mu^,^ or human fetal bone fragment^.^ Lapidot et a15 recently described a system that successfully allowed engraftment of adult human marrow in immunodeficient mice. In this model, unfractionated human BM was transplanted into irradiated severe combined immunodeficiency disorder (SCID) mice, and subsequent human hematopoiesis was dependent on intraperitoneal injections of recombinant human cytokines at 48-hour intervals for the duration of engraftment. The need for repeated injections of human cytokines suggests that previous failures of human marrow to proliferate in immunodeficient mice6 were caused by a lack of species-specific growth factors, rather than graft rejection.
UCCESSFUL GENE therapy of genetic diseases involving hematopoietic cells requires long-term expression of an exogenous gene after transfer into human bone marrow (BM) stem cells. Retroviral vector-mediated transduction of murine hematopoietic stem cells has been convincingly shown.'.' However, there has been no comparable demonstration of human hematopoietic stem cell transduction, because of the lack of an experimental in vivo transplantation system. Several groups have used xenogeneic BM transplantation (BMT) into immunodeficient mice to study human hematopoiesis, and such a system may be used to study gene transduction of human stem cells. Two of the models that have been developed require surgical implantation of human fetal liver and thy mu^,^ or human fetal bone fragment^.^ Lapidot et a15 recently described a system that successfully allowed engraftment of adult human marrow in immunodeficient mice. In this model, unfractionated human BM was transplanted into irradiated severe combined immunodeficiency disorder (SCID) mice, and subsequent human hematopoiesis was dependent on intraperitoneal injections of recombinant human cytokines at 48-hour intervals for the duration of engraftment. The need for repeated injections of human cytokines suggests that previous failures of human marrow to proliferate in immunodeficient mice6 were caused by a lack of species-specific growth factors, rather than graft rejection.
We report the development of a novel system that allows differentiation of mature hematopoietic cells from enriched human marrow progenitor cells transplanted into beige/nude/ xid (bnx) mice without surgery or subsequent manipulation of the animals. CD34+ progenitor cells, isolated from normal adult human marrow, were cotransplanted into btu mice along with primary human marrow stromal cells that had been engineered to secrete human interleukin-3 (IL-3). IL-3 is a species-specific cytokine, produced by T lymphocytes, that is required for survival and growth of primitive hematopoietic progenitors.' IL-3 acts in concert with the cytokines IL-6 and c-kit ligand, both produced by stromal cells, to cause progenitor cell proliferation. 8 We hypothesized that augmented IL-3 production would enhance the ability of stromal cells to support human hematopoiesis in vivo in immunodeficient mice. Engraftment of the engineered stroma produced a continuous physiologically relevant level of human IL-3 in the murine bloodstream for at least 4 months, obviating the need for repeated cytokine injections. Sustained in vivo human hematopoiesis was shown by the presence of human-specific colony-forming units (CFUs) and mature hematopoietic cells in the marrow, spleen, and blood of the bnx mice. The persistence of human hematopoietic cells was strongly dependent on the production of IL-3 by the cotransplanted human stroma.
To study gene transfer into human hematopoietic progenitor cells, CD34+ cells were transduced by retroviral vectors carrying the neomycin phosphotransferase (NEO) gene or a human glucocerebrosidase (GC) cDNA before cotransplantation. The stroma secreting IL-3 supported the in vivo survival of primitive human progenitor cells for up to 9 months in bnx mice. The human progenitors that recovered from the murine marrow were marked by the retroviral vectors and were capable of forming multilineage colonies in clonogenic assays. In addition, mature cells containing vector proviral DNA sequences continued to circulate in the blood stream of the mice for the duration of engraftment. Our system extends the period during which transduced human hematopoietic progenitor cells can be studied, and may allow the study of human stem cell transduction vector, which carries a normal human GC cDNA, was constructed and packaged as previously described.'' The titer of the LN vector was 1 X IO' infectious units/mL, and the titer of G2 was S x IOh/ mL. The L-IL-3-SN vector was constructed by inserting a normal human IL-3 cDNA into the LXSN vector."' The human IL-3 cDNA was provided by Dr Steven Clark (Genetics Institute Inc, Cambridge, MA), in the plasmid pXM." The cDNA was shortened to exclude 3' untranslated sequences that cause mRNA instability.'' The desired sequence was amplified by PCR using the following primers: S'CCGGATCCAAACATGAGCCGCCT-3' (sense) overlapping the ATG start codon and S'GCGGATCCATGACCCAGAGGTTTC-AGAA-3' (antisense), 60 bp after the termination codon. The polymerase chain reaction (PCR) product was cut with BamHI and cloned into the BamHI site of pLXSN.
MATERIALS AND METHODS

Retroviral vectors
The L-IL-3-SN plasmid was transfected into PE501 ecotropic packaging cells'" using Transfection reagent (Boehringer-Mannheim, Indianapolis, IN). The transiently produced virus, collected after 48 hours, was used to transduce PA3 I7 amphotropic packaging cells' (American Type Culture Collection, Rockville, MD: CRL 9078). The PA317 cells were cloned in 0.5 mg/mL active G418 (Geneticin; GIBCO, Grand Island, NY) and individual colonies were expanded and screened for neomycin-resistance titer on NIH 3T3 cells, and for IL-3 production by bioassay. A single clone (no. 9) with a titer of S X IOh/mL was chosen that produces I O pg IL-3/d/ IOd cells by bioassay.
To produce virus-containing supernatants, the PA3 17 VPF were plated at subconfluency in Dulbecco's modified Eagles medium with high glucose (GIBCO) and 10% heat-inactivated fetal calf serum (FCS: Irvine Scientific, Santa Ana, CA). The medium was changed the next day, then collected after 24 hours, filtered (0.45 pm) and frozen at -70°C.
All VPF were consistently negative for helper virus, when tested by PCR of target 3T3 cells for amphotropic env sequences as described.I4
Human BM. Normal human BM cells were obtained from screens used to filter marrow during harvest of allogeneic donors. Use of these samples was approved by the Committee on Clinical Investigations at Childrens Hospital Los Angeles. Light-density mononuclear cells were obtained by centrifugation of Ficoll-Hypaque (Sigma Chemical CO, St Louis, MO), and plated at a density of 5 X 10' cells/mL in Iscove's modified Dulbecco's medium (IMDM; GIBCO) with 20% FCS. Cells were incubated for 4 to 8 hours at 37°C with S% CO,, to allow adherence of endothelial cells before isolation of CD34" progenitors. Stromal cells. Spicules from unseparated BM were collected by gravity sedimentation and plated in stromal medium, which is IMDM with 15% FCS, 15% horse serum (Gemini Bioproducts, Calabasas, CA), mol/L 2-mercaptoethanol, IO-' m o l n hydrocortisone (Sigma), S0 U/mL penicillin G, 50 pg/mL streptomycin sulfate, and 2 mmol/L L-glutamine (Irvine Scientific). Subconfluent layers of primary stromal cells were split by trypsinization (trypsin-EDTA, Irvine Scientific), plated sparsely, and transduced at passage no. 2. Transduction with the L-IL-3-SN and LN vectors was achieved through four rounds of retroviral supernatant addition to the cultures for 2 hours each, with polybrene (hexadimethrine bromide; Sigma) at a findl concentration of 4 pg/mL. After transduction. stromal cells were selected in 0.75 mg/mL active G418 for 2 weeks, then cryopreserved. Stroma was not used in cotransplantation assays until passage no. S. At this point. hematopoietic cells had been eradicated. as shown by the absence of human CD4.5' cells by fluorescence activated cell sorter (FACS) analysis and immunohistochemistry.
IL-3 bioassay. Human IL-3 levels in tissue culture supernatants and mouse serum samples were measured by bioassay. which was found to be more sensitive than commercially available enzymelinked immunosorbent assay (ELISA) kits. The level of human IL-3 in each sample was quantitated by the ability to support growth of human CD34' hematopoietic progenitor-derived colonies.
Supernatants were collected for bioassay from confluent plates of IL-3-producing cell lines or primary stromal cultures 24 hours after medium replacement, sterile filtered, and stored frozen at -70°C. Murine serum samples were collected from the tail vein at various time., after cotransplantation, or obtained from a severed renal artery at the time of death. Blood was collected without heparin or EDTA, and allowed to coagulate. Serum was then removed from the pelleted sample. and stored at -70°C.
Methylcellulose medium lacking recombinant growth factors was used for the bioassay. The medium was IMDM with 30% FCS, I % bovine serum albumin (BSA), 50 U/mL penicillin G, SO pg/mL streptomycin sulfate, 2 mmol/L L-glutamine, IO-' M 2-mercaptoethanol, IO-' M hydrocortisone, and l .3% methylcellulose (Fisher Scientific, Fair Lawn, NJ). One microliter of cell culture supernatants (diluted 1: 100) or l0 p,L of each mouse serum sample (undiluted) were added into the medium, then SO0 or 1,000 CD34' progenitor cells were added to each plate and mixed. Each sample was tested in quadruplicate. One unit per milliliter recombinant human (rH) erythropoietin (Epogen: Amgen Corp, Thousand Oaks, CA) was added on day 4 of culture. Colonies that contained greater than 40 granulocyte or monocyte/macrophage cells and/or three erythroid bursts were enumerated on day 18. Resulting colony numbers were compared by linear regression analysis with a standard curve generated by plating an equal number of CD34-cells in a range of dilutions of rH IL-3 (Immunex Corp, Seattle, WA).
Trunsduction of CD34 ' progenitors. Human CD34+ cells were isolated from plastic nonadherent mononuclear BM fractions using the My10 monoclonal antibody (MoAb) and immunomagnetic beads as previously described.'< CD34' cells were plated at a density of IO5 cells/mL on monolayers of irradiated (20 Gy) allogeneic human marrow stromal cells in cytokine-containing medium. The medium was IMDM with 30% FCS, 1% BSA (Sigma), IO-" mol/L hydrocortisone. I O -' m o l k 2-mercaptoethanol, SO U/mL penicillin G. SO pg/ mL streptomycin sulfate, 2 mmol/L L-glutamine, SO U/mL rH ILh (R&D Systems, Minneapolis, MN), I O ng/mL rH IL-3 (Immunex), and SO ng/mL mast cell growth factor (MGF: a c-kit ligand from Immunex). The cells were precultured on the stroma with cytokines, without removal of the immunomagnetic beads, for 48 hours before addition of vector supernatant.
After the preculture period, CD34' BM progenitor cells were transduced by supernatant addition with stromal cell support, as first described by Moore et al." One-half volume of filtered supernatant from vector-producing fibroblasts was added at 12-hour intervals over a period of 48 hours. with polybrene to a final concentration of 4 pg/mL. The concentrations of IL-3, 1L-6, and MGF used for marrow preculture were maintained throughout the transduction period. After gene transfer, nonadherent cells were collected and pooled with adherent cells from the same flask, which were harvested by treatment with O.IS% collagenase (Sigma. type 8) in phosphatebuffered saline (PBS) with Ca" and Mg" (Irvine Scientific) for IS minutes at 37°C. Cells were washed, then plated twice in the cytokine-containing medium for 2-hour periods to permit adherence of the previously irradiated stromal cella. Transduced cells were plated For personal use only. on August 30, 2017. by guest www.bloodjournal.org From in methycellulose progenitor colony-forming assay, with and without G418, to measure gene transduction efficiency as described." The remaining cells were used directly for cotransplantation into immunodeficient mice.
Mice. bnx homozygous males (bg.bg/nu.nu/xid.xid) and females heterozygous for the nude allele (bg.bg/nu.+/xid.xid) were obtained from Dr Carl Hansen (National Institutes of Health, Bethesda, MD"). SCID mice (BALBlc-ByJ) were obtained from Jackson Laboratories (Bar Harbor, ME). All mice used in these experiments were bred in the animal facility at Childrens Hospital Los Angeles and housed under sterile conditions in microisolator cages (Lab Products Inc. Maywood, NJ). Cages, water bottles, and bedding were autoclaved and changed twice a week. Mice were fed y-irradiated Rodent Blox (Purina, Riverside, CA) and acidified water (pH = 3.0) ad libitum. Mice were cotransplanted at 6 weeks of age. The bnx mice were given one sublethal radiation dose of 500 rads delivered at a rate of 37 cGy/min (source: Cobalt-60 Eldorado S irradiator, AECL Medical, Ontario, Canada), 24 hours before transplantation. We did not observe radiation-induced death of bnx mice at this dosage, even without a subsequent transplant. SCID mice were administered one radiation dose of 400 rads, which was often lethal, even with subsequent transplantation of human marrow.
Cotransplantation. Before cotransplantation, IL-3-producing or control stromal cells were harvested by collagenase treatment as previously described.15 For each mouse to be transplanted, IO6 transduced stromal cells and 1 to 2 X 10' transduced human progenitor cells were harvested from their respective cultures, washed, and allowed to bind together in conical 15 mL polypropylene tubes (Becton Dickinson [BD], Franklin Lakes, NJ) for at least 2 hours before transplantation. Cell clumps were disaggregated with a 27G needle after washing in PBS (Irvine Scientific). Stromal cells pass through 27G needles with high viability, as confirmed by trypan blue counts and replating experiments. One million stromal cells and two million CD34' cells per mouse were injected via the tail vein in 0.2 cc PBS.
Tissue harvest and processing. Mice were killed by CO2 narcosis, 2 to 9 months after cotransplantation. Tissues were harvested and analyzed for the presence of human cells and vector DNA. Blood was collected in capillary tubes from a severed renal artery, yielding approximately 1 mL per mouse. Complete blood counts were done using a Unopette blood dilution system (BD, Rutherford, NJ) and hemocytometer. Blood samples were divided into portions for serum IL-3 level bioassay, PCR, and immunohistochemistry. Live cells were assayed by trypan blue exclusion. Nucleated cells were enumerated by lysing red blood cells (RBCs) in Turk's dye, then counting on a hemocytometer. Spleens were divided into three portions. One third was passed through a wire mesh sieve cup (Sigma) followed by a 25G needle to dissociate cells for FACS analysis. The second section was flash frozen in liquid nitrogen for DNA preparation and PCR analysis. The third portion was frozen for cryosectioning in Optimal Cutting Temperature compound (Tissue-Tek OCT; Miles Inc, Elkhart, IN) in square cryomolds (10 x IO X 5 mmol/L; Miles Inc, Lab-Tek division, Naperville, IL) by submersion in liquid nitrogen. BM was flushed from the tibiae and femurs of each mouse into I X PBS, dispersed with a fine needle, then used for FACS analysis, human-specific CFU plating, cryopreservation, and DNA preparation. Portions of each liver, lung, and kidney were frozen in OCT for tissue sections, and the remainders were snap frozen for DNA preparation and PCR analysis.
Antibody staining and FACS analysis. Single-cell suspensions from the marrow and spleen of cotransplanted mice were incubated for 10 minutes with Lysing Reagent (Ortho Diagnostic Systems Inc, Raritan, NJ) to rupture RBCs. Samples were then washed in a Sorvall cellwasher 2L (Ortho Diagnostic Systems Inc), and preincubated with unconjugated mouse Ig (Coulter, Hialeah, FL). Directly conjugated antibodies used to identify human-specific cell surface antigens were: HLE-l (anti-CD45; BD), My7-RDI (anti-CD13; Coulter), My9-RDl (anti-CD33; Coulter), HPCA-2 (anti-CD34; BD), Leu-5b (anti-CD2; BD), Leu-l2 (anti-CD19; BD), Leu-3a (anti-CD4; BD), Leu-2a (anti-CD8; BD), Leu-l9 (anti-CD56; BD), Leu-7 (anti-CD57; BD), anti-CD41 (Gentrak, Plymouth Meeting, PA), and antiglycophorin A (Gentrak). The antimouse CD45-R antibody (Immunoselect, Gaithersburg, MD) was used to identify murine leukocytes. After the incubation period, cells were washed and fixed in 2% paraformaldehyde. Samples were analyzed on a BD FACScan. In all experiments, parallel staining and FACS analyses were performed on normal murine and human controls. None of the human-specific antibodies used in our analyses cross-reacted with murine cells.
Zrnmunohistochernisfry. Tissues frozen in OCT blocks were cut into 4 pm sections and applied directly to superfrost-charged slides (Fisher, Pittsburg, PA). Slides were fixed in acetone, then blocked for 30 minutes with Qualex Blocking Reagent (American Qualex, La Mirada, CA). The human-specific primary antibodies HLE-l and My9-RDl were applied at a 1: 1,000 dilution in Tris-buffered saline (TBS; pH 7.0). Immunohistochemical staining was performed as directed in the Supersensitive Streptavidin kit (Biogenex, San Ramon, CA), and developed with Fast Red chromogen (Biogenex) or Vectastain Blue (Vector Labs, Burlingame, CA). Slides were counterstained in hematoxylin (Sigma) for I O minutes, then washed in HzO, air dried, and fixed using Aquamount (Lerner Laboratories, Pittsburg, PA).
For cytospin analysis of peripheral blood samples, whole blood was harvested from mice using heparinized capillary tubes and transferred to 2-mL eppendorf tubes. To 200-pL samples, 1 m1 Lysing reagent was added. Tubes were incubated at 37°C for 10 minutes, then spun for 20 seconds in a tabletop microfuge (Costar, Cambridge, MA), at 3,000 rpm. Cell pellets were resuspended in 1 X PBS/SO% FCS, then applied to slides using a Shandon cytocentrifuge (850 rpm for 4 minutes). Slides were air dried several hours, fixed 5 minutes in acetone, and stored at -20°C until use. Immunohistochemistry was performed as described for tissue sections, with omission of the blocking steps.
Hurnan-spec$c CFU assay. To determine the number of human hematopoietic progenitor cells engrafted within the murine BM, marrow cells harvested from each mouse were plated in a modified version of the human-specific CFU granulocyte-macrophage (CFU-GM) assay previously described by Kamel-Reid and Dick.6 The medium used was IMDM with 30% FCS, 1% BSA, 1.3% methylcellulose, 50 U/mL penicillin G , 50 pg/mL streptomycin sulfate, 2 mmoVL L-glutamine, m o m hydrocortisone, m o a 2-mercaptoethanol, and I O ng/mL rH IL-3 (Immunex Corp). rH erythropoietin (Epoietin alpha; Amgen Corp) was added on day 4 of culture at a concentration of 1 U/mL. Methylcellulose, FCS, and BSA were previously screened to provide maximal CFU-GEMM development from human CD34+ cells, Plastic non-adherent cells (5 X lo4 to 2 X IO') from engrafted and control mice were plated in duplicate in 1 mL of the medium in a gridded culture dish (Nunc, Naperville, IL), with and without G418 (1 mg/mL active compound). Colonies were enumerated as previously described." In this medium, growth of murine colonies was observed only when stromal cells had contaminated the CFU dish. Therefore, any plates containing adherent stromal or fibroblastic colonies were discarded.
For clonal analysis, single colonies were plucked from the dish using a micropipette tip, washed twice in 1 mL PBS, and divided into two portions. The first sample was lysed for PCR analysis of vector sequences and the second sample was used to generate cytospin slides for immunohistochemical analysis.
PCR. For amplification of LN vector sequences from whole cell lysates, previously described N E 0 primers" were used in 1.5 mmoll L Mg2+ PCR buffer (Perkin Elmer-Cetus, Nonvalk, CT) with an 
RESULTS
L-IL-3-SN transduction of BM stromal cells. Primary human stromal cells were transduced at second passage by the addition of supernatant from the VPF clone PA317L-IL-3-SN no. 9 or from VPF producing the control vector LN." After selection of the transduced stromal cells in G418 and re-expansion to confluency, supernatant was harvested for bioassay of human IL-3 production. IL-3 levels produced by transduced stroma and VPF were measured from supernatant collected from lo6 cells plated 24 hours earlier. The human IL-3 level in each sample was quantitated by comparing the numbers of CD34' progenitor-derived colonies supported by IL-3 in the supernatant to that generated by a range of dilutions of rH IL-3. Recombinant IL-3 gave a linear dose response (Fig IA) . Human CD34+ cells were not observed to form colonies in the absence of IL-3, but responded with a 20-fold increase in colony number to IL-3 concentrations as low as 0.1 pg/mL methylcellulose medium. The bioassay was found to be more sensitive than a commercially available ELISA kit (R&D Systems) that could not detect IL-3 concentrations of 60 pg/mL or lower.
As measured by bioassay, the PA317/L-IL-3-SN no. 9 cell line produced 10 pg human IL-3/106 cells/d. PA317 packaging cells transduced by the parental LN vector produced no detectable IL-3 bioactivity. Primary stromal cultures from eight different normal human donors transduced by L-IL-3-SN were tested, and produced an average of 15 pg (?7.6, SEM) IL-3/10h cellsld. Human stromal cells transduced by the LN vector did not produce detectable levels of IL-3. It is possible that synergistic activity from the stromal cells could produce augmented IL-3 readings in the bioassay. Therefore, supernatants from the VPF and stromal cells were measured by ELISA for human IL-3, which gave similar values. Verification of serum IL-3 levels by ELISA was not possible.
Human stromal cells resistant to the selective agent G418 could be recovered from the spleen, and occasionally lung or liver, of the cotransplanted bnx mice for as long as 9 months. This directly shows that the stroma persists in the mice for the duration of hematopoietic cell engraftment. Transduced human stromal cells were not recovered from the marrow of the mice.
Human IL-3 detection in the btood of long-term engrafted bnx/hu mice. The level of human IL-3 in murine plasma was estimated in the bioassay by the ability to support growth of human CD34' hematopoietic progenitor-derived colonies. Human IL-3 was detected in the serum of bnx/hu mice 4 months after cotransplantation of human progenitor cells and L-IL-3-SN transduced stroma. Six mice that had received IL-3-producing stroma had a mean of 607 (261 SEM) pg human IL-3/mL serum, maintained for at least 4 months after cotransplantation. Plasma from mice transplanted with control (LN) stroma and human CD34' cells had no detectable human IL-3 bioactivity.
In a time-course experiment, human IL-3 levels were sequentially analyzed in the serum of mice cotransplanted with human progenitor cells and three types of human stroma: L-IL-3-SN transduced, LN transduced, and irradiated (20 Gy) L-IL-3-SN transduced (Fig 1B) . Two mice that received L-IL-3-SN-transduced stroma had serum IL-3 levels averaging 200 pg/mL at the initial time-point, 1 week post-BMT. The level increased to 500 pg/mL by 5 weeks post-BMT. At the time of harvest, 16 weeks posttransplantation, the two mice had serum IL-3 levels of 300 and 400 pg/mL. The two mice that received irradiated L-IL-3-SN-transduced stroma had an average of 50 pg/mL human IL-3 in serum samples taken at 1 week post-BMT, but human IL-3 was not detected in the serum of either animal at subsequent time-points. The two mice that received LN-transduced human stroma had no detectable levels of human IL-3 at any time-point.
Although murine cells do not respond to human IL-3," it
For personal use only. on August 30, 2017. by guest www.bloodjournal.org From was possible that the engrafted human marrow or stromal cells might produce other cytokines that could perturb murine hematopoiesis. Therefore, complete blood counts were performed on six mice that had been cotransplanted with human CD34' cells and IL-3 producing stroma. The cell counts were compared with those obtained from six control mice of the same age that had been sublethally irradiated, but not transplanted. There was no significant variation between the counts obtained from the two groups of mice. when analyzed 4 months after irradiation (data not shown).
Annlysis of hlrman kemntopoiesis in brtx/Itrr mice. To assess the importance of human IL-3 production by the stromal cells, we compared the human hematopoietic cell engraftment levels of mice cotransplanted with human CD34' progenitor cells and IL-3 producing stroma to the engraftment levels of mice cotransplanted with human progenitors and control (LN transduced) stroma. The primary measure of engraftment of human hematopoietic cells in the mice was quantitation by immunofluorescence of BM cells expressing the human common leukocyte antigen, CD45. Figure 2 shows the species-specificity of the anti-CD45 MoAbs used in our experiments; marrow from a control bnx mouse did not react with the antihuman CD45 antibody and normal human marrow did not react with the antirnurine CD45 antibody. In bnx mice not transplanted with human cells, there were never greater than 0.02% cells that fell into the human CD45' window. Therefore, we can confidently state that we can distinguish 1% from background. FACS analyses of a typical well-engrafted animal show the presence of 10.14% human CD45' cells in the marrow, and 21.18% in the spleen, 4 months after cotransplantation of human CD34' cells and IL-3-producing stroma.
A total of 86 immunodeficient mice, of three different strains, were used in long-term cotransplantation experiments. The only strain which successfully accepted the human marrow xenograft was the C3Hhgouti bnxIx (Table l) . Forty-one mice of this strain were used. Twenty-six were cotransplanted with human CD34' cells and IL-3-producing stroma. Two to 9 months after cotransplantation, 22 of the 26 mice in this group had greater than 1% human cell engraftment in their BM. Engraftment levels averaged 5.6% (50.96 SEM) human CD45' cells, and are summarized in Fig 3 . Two mice were killed 9 months after cotransplantation, and had retained 1% to 2% human CD45' cells in the BM. Fifteen C3Hhgouti bnx mice were cotransplanted with human CD34' cells and control, LN-transduced stroma. Only 3 of the I 5 control mice had greater than 1 % human CD45' cells surviving in the BM 2 to 5 months after cotransplantation (Fig 2) . The average engraftment level of the control mice was 0.64% (+0.26 SEM) human CD45' cells. The group of mice cotransplanted with human IL-3-producing stroma had a significantly higher level of engraftment with human hematopoietic cells than the group cotransplanted with control stroma (P < .00001 by the one-tailed t-test).
A total of 26 SCID mice, and 21 C57bV6j bnx mice were cotransplanted with CD34' cells and stroma transduced by L-IL-3-SN. No mouse of either strain was shown by FACS analysis or immunohistochemistry to have greater than 1% human CD45+ cells in the BM, spleen, or blood when harvested 2 weeks or 2 months after cotransplantation.
ImmunophenoQpic characterization of engrafted human hematopoietic cells. To further characterize the engrafted human cells from the C3Wagouti bnx mice cotransplanted with human progenitors and IL-3-producing stroma, additional FACS and immunohistochemical analyses of marrow, spleen, and peripheral blood were performed 4 months after BMT. Peripheral blood samples from 4 mice contained an average of 7.7% human hematopoietic cells that were positive by immunohistochemistry for human CD45 (Fig 4A) . Fifty-six percent of the circulating human CD45+ blood cells coexpressed CD33, indicating a myelomonocytic lineage.
By FACS analysis, spleen cells from 10 bnx/hu mice had a mean of 6.1% human CD45' cells, of which 52% expressed CD33. In spleen sections analyzed by immunohistochemistry, human CD45+ cells were distributed singly or in clusters throughout the tissue (Fig 4 B and C) . The CD33' myelomonocytic cells were found scattered throughout the spleens (Fig 4D) . Splenic sections from mice cotransplanted with CD34+ cells and control stroma did not contain human CD45' cells (Fig 4E) .
BM cells from 10 bnx/hu mice that had greater than 1% human CD45' cell engraftment were analyzed by FACS for the expression of additional human cell surface antigens ( Table 2 ). The average percentage of human CD45 cells in the marrow of this group of mice was 7.5% ( Z l .35 SEM). Human cell surface antigens that were detected by FACS analysis on discrete cell populations included the myelomonocytic markers CD33 and CD13, the progenitor cell marker CD34, the megakaryocyte marker CD4 I , and the lymphocyte marker CD2. We did not detect mature human erythroid cells (glycophorin A') in the marrow or peripheral blood of cotransplanted mice, perhaps because of the absence of human erythropoietin. Cells of the B lineage, which expressed CD19. were present in only one mouse, as 2% of the total human CD45' cells.
The discovery that approximately one-third of the human cells engrafted in the mice expressed the T lymphoid marker CD2 (2.6% CD2'/7.5% CD45') warranted further investigation. The development of human CD2' cells might suggest that a human pluripotent stem cell capable of both myeloid and lymphoid cell production had engrafted. To rule out the possibility that the CD2' population had arisen from mature T cells that had contaminated the starting CD34' cell population, we performed a series of transplants in which the initial marrow inoculum was T depleted before progenitor isolation. BM from a normal donor for haploidentical transplantation of a child with severe combined immune deficiency was depleted of T cells using the soybean agglutinidsheep RBC E-rosette technique. The level of clonogenic T cells was decreased two logs by the T depletion. CD34+ cells were then isolated from the T-depleted marrow and injected into bnx mice with IL-3-producing stroma. We found that Tdepleted human marrow produced the same level of CD2' cells in the long-term engrafted bnxhu mice (3.6% CD2'/ 9.1 % CD45'), despite an absence of detectable CD2' cells in the starting CD34' population. Therefore, it would appear that early T cells had developed from progenitor cells transplanted into the bnx mice. Whether these cells arose from a pluripotent stem cell will be the subject of future study, by retroviral marking and clonal integration analysis.
Muintenancc of human rnultilineuge colony-forming progenitors in bnx/hu mice. Because human CD34+ cells were detected in the BM of the long-term engrafted bnxhu mice, we determined their colony-forming potential. A methylcellulose-based assay was used that specifically allowed the granulocyte with a segmented nucleus is seen runounded by t y p i c a l murine granulocytes with ring nuclei, which do not bind the antihuman CD45 antibody, HE-l. (B) Human CD&+ cells in a spleen suction from bm/hu mouse no. 7 in Table 3; growth of colonies from human, but not murine, multipotent hematopoietic progenitors. rH L-3 and erythropoietin were the only cytokines added to the medium. Marrow from nontransplanted bnx mice did not form colonies under these conditions, showing the strict species-specific activity of human IL-3 to promote human, but not murine, hematopoiesis. Marrow samples harvested from 14 bnxihu mice transplanted with human CD34+ cells and IL-3-producing stroma were tested for the presence of human colony-forming progenitors. Nine mice in this group had at least 40 human CFUs per lo5 marrow cells plated 2 to 9 months post-BMT (Table  3) . Primitive human progenitor cells were maintained in vivo in the BM of these mice, as shown by outgrowth of mixed lineage colonies containing myelomonocytic and hemoglobinized cells in the human-specific clonogenic assay ( Fig  4F, insert) . Of five mice that had been cotransplanted with human CD34+ cells and control (LN) stroma, none had clonogenic human progenitor cells in their marrow, 2 to 4 months post-BMT (Table 3) .
Engraftment of retroviral vector-transduced human progenitors in bnx/hu mice. We next determined the percentage of primitive human progenitor cells that had been successfully transduced in vitro by the retroviral vectors LN and G2 and sustained in the murine marrow. Five mice had been cotransplanted with IL-3-producing stroma and human CD34' cells that had been transduced in vitro by the LN vector." LN carries the N E 0 gene, and encodes resistance to the selective agent G418. After transduction and before transplantation, the marrow contained 37% G4 18-resistant CFU. Four months after cotransplantation, the two mice that were well engrafted had maintained 34% and 21 % G418-resistant human progenitor cells in their marrow (Table 3) . Two mice from the same experiment were analyzed 9 months after transplantation. One mouse had maintained 29% G4 18-resistant human progenitor cells in its marrow. Two mice that had 5 1% engraftment as well as one mouse transplanted with LN transduced CD34+ cells and control stroma did not have detectable levels of G418-resistant human colonies.
To confirm the identity of the G418-resistant mixed lineage colonies, each was individually picked from the plate and analyzed by immunohistochemistry for human CD45 (Fig 4F) and by PCR for vector sequences. All G418-resistant mixed lineage colonies that were analyzed (20120) consisted solely of human CD45+ cells, and contained integrated N E 0 DNA (Fig 5A) . These results show the persistence, for at least 9 months, of transduced, multipotent human progenitor cells in the marrow of the animals cotransplanted with IL-3 -producing stroma. Mice no. 6 to 14, shown in Table 3 , were cotransplanted with human progenitor cells transduced in vitro by the G2 retroviral vector" and IL-3-producing stroma. G2 carries a human GC cDNA that is relevant to gene therapy for Gaucher disease. PCR analysis of marrow, spleen, and peripheral blood from these animals was used to verify the presence of vector DNA in each tissue (Table 3) . Each bnx/ hu mouse that had greater than 1% human marrow engraftment also had G2 vector DNA in marrow and blood, and often in spleen cells. Liver and kidney samples from the same animals did not contain detectable provirus. No vector DNA was detected by PCR analysis in any tissue from mice cotransplanted with the control (LN) stroma (Table 3) , again showing the importance of human IL-3 in maintaining human hematopoiesis in the engrafted mice.
Human-specific colonies were grown from the marrow of a second set of mice 4 months after cotransplantation with human CD34' cells transduced in vitro by the G2 vector and IL-3-producing stroma. Individual colonies were analyzed by PCR for the presence of integrated G2 provirus (Fig SB) . G2 vector sequences were present in 22/83 (27%) of the human colonies, including 14 multilineage colonies containing both myeloid and erythroid cells. Therefore, the G2 vector had transduced long-lived human hematopoietic progenitor cells in vitro, which then survived for 4 months in the mice, and retained multilineage colony-forming potential.
DISCUSSION
We have developed a novel cotransplantation system that allows sustained human hematopoiesis in bnx mice. starting with a CD34-enriched cell population. Coinjection of primary human stroma engineered to secrete human IL-3 led to the persistent presence of human IL-3 in the bloodstream of the immunodeficient mice. The serum concentration detected in the mice (mean = 607 pg/mL) was physiologically significant, and caused 68% maximal human marrow colony formation in vitro. Continuous IL-3 production from the stroma was necessary and sufficient to support human hematopoiesis: mice transplanted with either control stroma. containing only a N E 0 gene, or with irradiated IL-3-transduced stroma lacked detectable circulating human IL-3 and did not have significant numbers of human hematopoietic cells after 4 months. Continuous in vivo production of human IL-3 from the stroma eliminated the need for repeated injections of growth factor that may decrease the labor involved in manipulating recipient mice and allow greater utilization of such experimental systems.
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The engraftment from CD34' cells in the presence of IL-3-secreting stroma was documented by the presence of human CD45+ cells in the peripheral blood, marrow, and spleen of recipient mice. The human cells were mostly of the granulocytic and myeloid lineages, but there were also significant populations of cells expressing the lymphoid antigen CD2. A small percentage of cells (0.76%) expressing the human progenitor cell antigen CD34 were seen in the marrow of the mice. The engrafted cells were functional human hematopoietic progenitor cells, as shown by the growth of human multilineage colonies from marrow samples taken from the mice after 4 months.
We reasoned that it may be necessary to supply human IL-3 to support human hematopoiesis because IL-3 is made in extremely low levels by stromal cells," and endogenous murine IL-3 would not act on human hematopoietic cells. Additionally, the lack of activity of human IL-3 on murine hematopoiesis should prevent the engineered stroma from stimulating the endogenous murine marrow, which could then compete against the human marrow or even result in a myeloproliferative syndrome. The lack of stimulation of the murine hematopoetic system by stroma-producing human IL-3 was documented by the normal blood counts in the recipient mice.
However, the observation that IL-3 impedes B-lymphoid differentiation of murine progenitors in vitroz3 suggests that the use of stroma-producing IL-3 may account for the absence of mature human B-lymphoid cells derived from the human CD34+ progenitor cells in the mice. The human IL-3 in the cotransplanted mice might have driven progenitor cells toward myelomonocytic differentiation and away from lymphopoiesis. The use of cotransplanted stroma expressing other cytokines, such as the c-kit ligand, IL-2, or IL-7, may give different patterns of human hematopoiesis in the mice, including production of lymphocytes. Potentially, these human cytokines may have undesired effects on the endogenous murine hematopoietic system that could limit their use.
Three different strains of immunodeficient mice were used in long-term cotransplantation experiments, yet the only strain that successfully accepted the human marrow xenograft was the C3H agouti bnx." The early graft failure seen in the SCID and C57bV6j bnx mice leads us to suspect that these particular strains of mice were able to produce an immune response against the xenograft (possibly mediated by natural killer cells) and reject the human cells.
We have used this model of in vivo human hematopoiesis to study retroviral-mediated transduction of human hematopoietic progenitor cells. CD34+ cells were transduced with retroviral vectors carrying either the N E 0 gene or the human GC cDNA before cotransplantation. Human multipotential colony-forming progenitors that survived in the marrow of the cotransplanted mice for as long as 9 months were shown to contain the proviral genes by DNA PCR and by the expression of G418-resistance. Mature human hematopoietic cells containing vector DNA sequences were also found in the murine circulation for the same period of time. These observations lead us to conclude that primitive human progenitor cells were transduced in vitro before cotransplantation and sustained in vivo.
It would be detrimental if conditions required to cause cells to cycle to allow retroviral vector integration caused a loss of pluripotentiality. Although we are unable to determine the effects on true stem cells, our ability to recover transduced multipotent human progenitor cells from the marrow of the mice 9 months after cotransplantation shows that the 5 days of in vitro manipulation used for gene transfer did not eliminate the long-term mixed-lineage colony-forming potential of the human CD34' progenitors.
The ideal target cell for gene therapy using BM is the pluripotent hematopoietic stem cell. It is not possible to state that we have shown gene transduction of such pluripotent cells, because of the lack of B-lymphocyte production. Nevertheless, we have extended the period during which it is possible to study human multilineage colony-forming human cells by at least 7 months over the standard 2-month longterm culture-initiating cell assay.x The system described here should also permit characterization of hematopoietic differentiation from subpopulations of human marrow cells, such as CD34' cells lacking lineage markers, the CD38 antigen, or surface DR expression. If conditions can be developed that permit pluripotent human hematopoiesis in vivo, it would then be possible to determine whether human stem cells had been transduced by showing common retroviral integration site patterns in cells of both myeloid and lymphoid lineages. Therefore, the immunodeficient mouse, transplanted with stroma producing human cytokines, may be a valuable model to study vector persistence and expression in differentiating human hematopoietic cells, as an in vivo model for human BM stem cell gene therapy.
